MX2012001469A - Reparacion regioselectiva de derivados de 2-amino-5-trifluorometil pirimidina. - Google Patents

Reparacion regioselectiva de derivados de 2-amino-5-trifluorometil pirimidina.

Info

Publication number
MX2012001469A
MX2012001469A MX2012001469A MX2012001469A MX2012001469A MX 2012001469 A MX2012001469 A MX 2012001469A MX 2012001469 A MX2012001469 A MX 2012001469A MX 2012001469 A MX2012001469 A MX 2012001469A MX 2012001469 A MX2012001469 A MX 2012001469A
Authority
MX
Mexico
Prior art keywords
data
group
formula
optionally substituted
suitable substituents
Prior art date
Application number
MX2012001469A
Other languages
English (en)
Spanish (es)
Inventor
Juergen Schnaubelt
Guenter Linz
Gerd Kraemer
Sabrina Kusserow
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42712695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012001469(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2012001469A publication Critical patent/MX2012001469A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2012001469A 2009-08-14 2010-08-13 Reparacion regioselectiva de derivados de 2-amino-5-trifluorometil pirimidina. MX2012001469A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09167934 2009-08-14
PCT/EP2010/061840 WO2011018518A1 (en) 2009-08-14 2010-08-13 Regioselective preparation of 2 -amino-5-trifluoromethylpyrimidine derivatives

Publications (1)

Publication Number Publication Date
MX2012001469A true MX2012001469A (es) 2012-02-22

Family

ID=42712695

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001469A MX2012001469A (es) 2009-08-14 2010-08-13 Reparacion regioselectiva de derivados de 2-amino-5-trifluorometil pirimidina.

Country Status (17)

Country Link
US (1) US8933227B2 (cg-RX-API-DMAC7.html)
EP (1) EP2464634B1 (cg-RX-API-DMAC7.html)
JP (1) JP5539519B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120046248A (cg-RX-API-DMAC7.html)
CN (1) CN102471287A (cg-RX-API-DMAC7.html)
AR (1) AR077925A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010283713A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012002971A2 (cg-RX-API-DMAC7.html)
CA (1) CA2767965A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012000278A1 (cg-RX-API-DMAC7.html)
EA (1) EA201200282A1 (cg-RX-API-DMAC7.html)
IL (1) IL217112A0 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN01342A (cg-RX-API-DMAC7.html)
MX (1) MX2012001469A (cg-RX-API-DMAC7.html)
NZ (1) NZ597538A (cg-RX-API-DMAC7.html)
TW (1) TW201124385A (cg-RX-API-DMAC7.html)
WO (1) WO2011018518A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515372A (ja) * 2008-03-20 2011-05-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリミジン類の位置選択的製造法
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
CN102887860B (zh) * 2012-09-29 2015-07-01 上海泰坦科技有限公司 4-氯-6-三氟甲基嘧啶类化合物的制备方法
JP6391985B2 (ja) * 2014-05-16 2018-09-19 東ソー・ファインケム株式会社 2−置換−4−(2,2,2−トリフルオロエトキシ)−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法
JP6391988B2 (ja) * 2014-05-21 2018-09-19 東ソー・ファインケム株式会社 5−(トリフルオロメチル)ピリミジン誘導体の製造方法及び新規5−(トリフルオロメチル)ピリミジン誘導体
JP6262079B2 (ja) * 2014-06-02 2018-01-17 東ソー・ファインケム株式会社 4−(2,2,2−トリフルオロエトキシ)−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法
JP6431294B2 (ja) * 2014-06-16 2018-11-28 東ソー・ファインケム株式会社 5−(トリフルオロメチル)ピリミジン誘導体及びその製造法
JP6479486B2 (ja) * 2015-01-16 2019-03-06 東ソー・ファインケム株式会社 4−アルコキシ−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262A (ja) 1986-03-05 1987-01-06 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物の製造方法
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
CA2463989C (en) 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
DE10161763A1 (de) 2001-12-15 2003-07-17 Bayer Cropsience Ltd Neues herbizides Verfahren
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003231231A1 (en) 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
RS20050363A (sr) 2002-11-28 2007-11-15 Schering Aktiengesellschaft, Chk-,Pdk- I Akt-INHIBITORNI PIRIMIDINI, NJIHOVA PROIZVODNJA I UPOTREBA KAO FARMACEUTSKIH SREDSTAVA
GEP20084357B (en) 2002-12-20 2008-04-29 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005023780A1 (en) 2003-09-05 2005-03-17 Pfizer Products Inc. Selective synthesis of cf3-substituted pyrimidines
CN100584832C (zh) 2003-09-18 2010-01-27 诺瓦提斯公司 可用于治疗增殖性病症的2,4-二(苯基氨基)嘧啶类
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
AP2241A (en) 2004-05-14 2011-06-01 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth.
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
JP2008505910A (ja) 2004-07-08 2008-02-28 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Pkc−シータのインヒビターとして有用なピリミジン誘導体
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
EP1841760B1 (en) 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
EP1705177A1 (en) 2005-03-23 2006-09-27 Schering Aktiengesellschaft N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents
EP1888561A1 (en) 2005-05-05 2008-02-20 AstraZeneca AB Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
CA2626375A1 (en) 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US8722884B2 (en) 2005-12-01 2014-05-13 Verastem, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
JP4332590B2 (ja) 2005-12-21 2009-09-16 ファイザー・プロダクツ・インク 異常細胞増殖を治療するためのピリミジン誘導体
TW200804364A (en) 2006-02-22 2008-01-16 Boehringer Ingelheim Int New compounds
WO2007115999A1 (en) 2006-04-10 2007-10-18 Boehringer Ingelheim International Gmbh 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer
US8623887B2 (en) 2006-05-15 2014-01-07 Boehringer Ingelheim International Gmbh Compounds
US8466318B2 (en) 2006-05-18 2013-06-18 Boehringer Ingelheim International Gmbh Method of preparing chiral cyclic β-aminocarboxamides
DE102006027156A1 (de) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
EP2041132A2 (en) 2006-07-06 2009-04-01 Boehringer Ingelheim International GmbH New compounds
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
WO2008040951A1 (en) 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
US20080255155A1 (en) 2006-10-18 2008-10-16 Stephane Raeppel Kinase inhibitors and uses thereof
RU2009112496A (ru) 2006-10-19 2010-11-27 Ф. Хоффманн-Ля Рош Аг (Ch) Аминометил-4-имидазолы
NZ576425A (en) 2006-10-23 2012-04-27 Cephalon Inc Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
AU2007332654B2 (en) 2006-12-13 2013-06-20 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
EP2099771A1 (en) 2006-12-19 2009-09-16 Genentech, Inc. Pyrimidine kinase inhibitors
EP1939185A1 (de) 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs
WO2008079346A1 (en) 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
US20100144706A1 (en) 2006-12-22 2010-06-10 Boehringer Ingelheim International Gmbh Compounds
TW200902010A (en) 2007-01-26 2009-01-16 Smithkline Beecham Corp Anthranilamide inhibitors of aurora kinase
US7947698B2 (en) 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
JP4782239B2 (ja) 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
BRPI0814432A2 (pt) 2007-07-17 2017-05-09 Rigel Pharmaceuticals Inc pirimidinadiaminas substituídas por amina cíclica como inibidores de pkc
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
BRPI0815979A2 (pt) 2007-08-28 2017-06-13 Irm Llc compostos e composições com inibidores de quinase, bem como uso dos mesmos
WO2009063240A1 (en) 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
CA2707653A1 (en) 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
ES2389752T3 (es) 2007-12-14 2012-10-31 Ardea Biosciences, Inc. Inhibidores de la transcriptasa inversa
UY31714A (es) 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
JP2011515372A (ja) 2008-03-20 2011-05-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリミジン類の位置選択的製造法
AU2009262198B2 (en) 2008-06-25 2012-09-27 Irm Llc Pyrimidine derivatives as kinase inhibitors
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2179991A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2179992A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
UY32240A (es) 2008-11-14 2010-06-30 Boeringer Ingelheim Kg Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines

Also Published As

Publication number Publication date
WO2011018518A1 (en) 2011-02-17
IN2012DN01342A (cg-RX-API-DMAC7.html) 2015-06-05
JP5539519B2 (ja) 2014-07-02
NZ597538A (en) 2014-05-30
CL2012000278A1 (es) 2012-10-12
AR077925A1 (es) 2011-10-05
CN102471287A (zh) 2012-05-23
KR20120046248A (ko) 2012-05-09
US8933227B2 (en) 2015-01-13
CA2767965A1 (en) 2011-02-17
EP2464634B1 (en) 2016-11-30
BR112012002971A2 (pt) 2015-10-13
AU2010283713A1 (en) 2012-02-02
US20110190499A1 (en) 2011-08-04
JP2013501759A (ja) 2013-01-17
IL217112A0 (en) 2012-02-29
EA201200282A1 (ru) 2012-09-28
EP2464634A1 (en) 2012-06-20
TW201124385A (en) 2011-07-16

Similar Documents

Publication Publication Date Title
MX2012001469A (es) Reparacion regioselectiva de derivados de 2-amino-5-trifluorometil pirimidina.
Bamborough et al. A chemical probe for the ATAD2 bromodomain
WO2011065708A3 (ko) IPv6 주소 및 접속정책 관리 시스템 및 방법
GB2473171A (en) Information rights management
US20130007879A1 (en) Method of and Apparatus for Monitoring for Security Threats in Computer Network Traffic
MY175911A (en) Method and system protecting against identity theft or replication abuse
WO2013009044A3 (ko) 특수 권한 기반의 내장 sim의 mno 변경방법 및 그를 위한 내장 sim과 기록매체
TWI268687B (en) Cipher key setting system, access point, and cipher key setting method
WO2010150052A3 (en) Methods and apparatuses for avoiding denial of service attacks by rogue access points
WO2012025826A3 (en) Method and system for securing accounts
WO2013052377A3 (en) Secure integrated cyberspace security and situational awareness system
IN2014DN07530A (cg-RX-API-DMAC7.html)
WO2009122295A3 (en) Method for monitoring the unauthorized use of a device
WO2013036011A3 (ko) 내장 uicc의 프로파일 관리방법 및 그를 이용한 내장 uicc, 내장 uicc 탑재 단말과, 프로비저닝 방법 및 mno 변경 방법
WO2008011576A3 (en) System and method of securing web applications across an enterprise
WO2013103640A2 (en) Methods and apparatuses for maintaining secure communication between a group of users in a social network
WO2012074332A3 (ko) 무선 단말기 및 이를 이용한 네트워크 접속 관리 방법
JP5099646B2 (ja) 無線lanアクセスポイント、無線lan端末、無線lan不正防止システム、方法及びプログラム
CN101860850B (zh) 一种利用驱动实现移动终端锁网或锁卡的方法
WO2010078172A3 (en) Optimizing security bits in a media access control (mac) header
Kang et al. Quantitative methodology to assess cyber security risks of SCADA system in electric power industry
CN103312518A (zh) 安全管理数据库信息的方法
Kim et al. A study on the improvement of effectiveness in national cyber security monitoring and control services
KR101557857B1 (ko) 무선침입방지시스템의 탐지장치
WO2012024504A3 (en) Communication and processing system for derivative offsets

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal